Methods for preparing T-cells for cell therapy

Details Methods for preparing T-cells for cell therapy Methods for preparing T-cells for cell therapy

2010-06-17

2011-12-06

Belyavskyi, Michail (Department: 1644)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Primate cell, per se

C435S377000

Reexamination Certificate

active

08071374

ABSTRACT:
T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradable devices are mixed with the T-cells sufficiently so that the one or more agents cross-link with the T-cells' surface moieties and deliver a signal to the T-cells to enhance immunostimulatory capabilities.

REFERENCES:
patent: 4279249 (1981-07-01), Vert et al.
patent: 5126132 (1992-06-01), Rosenberg
patent: 5443983 (1995-08-01), Ochoa et al.
patent: 5766920 (1998-06-01), Babbitt et al.
patent: 5806529 (1998-09-01), Reisner et al.
patent: 5846827 (1998-12-01), Celis et al.
patent: 6040177 (2000-03-01), Riddell et al.
patent: 6194207 (2001-02-01), Bell et al.
patent: 6251385 (2001-06-01), Terman
patent: 6255073 (2001-07-01), Cai et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6500193 (2002-12-01), Bezemer et al.
patent: 6511511 (2003-01-01), Slivka et al.
patent: 6514286 (2003-02-01), Leatherbury et al.
patent: 6534055 (2003-03-01), June et al.
patent: 6572894 (2003-06-01), Rossling et al.
patent: 6867041 (2005-03-01), Berenson et al.
patent: 6887466 (2005-05-01), June et al.
patent: 6905680 (2005-06-01), June et al.
patent: 6905681 (2005-06-01), June et al.
patent: 6905874 (2005-06-01), Berenson et al.
patent: 7402431 (2008-07-01), Har-Noy
patent: 7435592 (2008-10-01), Har-Noy
patent: 7592431 (2009-09-01), Har-Noy
patent: 7678572 (2010-03-01), Har-Noy
patent: 2002/0127208 (2002-09-01), Waller et al.
patent: 2003/0004578 (2003-01-01), Brown et al.
patent: 2003/0175272 (2003-09-01), Gruenberg
patent: 2003/0215946 (2003-11-01), Nair et al.
patent: 2005/0065593 (2005-03-01), Chu et al.
patent: 2005/0191746 (2005-09-01), Van et al.
patent: 2006/0036331 (2006-02-01), Lu et al.
patent: 2006/0121021 (2006-06-01), Hunig
patent: 0319012 (1989-06-01), None
patent: 9412196 (1994-06-01), None
patent: 9746256 (1997-12-01), None
patent: 9924045 (1999-05-01), None
patent: 0162895 (2001-08-01), None
patent: 03024989 (2003-03-01), None
patent: 03038062 (2003-05-01), None
patent: 2004004768 (2004-01-01), None
patent: 2005001074 (2005-01-01), None
patent: 2005081982 (2005-09-01), None
patent: 2005084276 (2005-09-01), None
Gabrilovich et al. “Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.” Cellular Immunology, 1996, vol. 170, No. 1, pp. 111-119.
Gale et al. “How does bone-marrow transplantation cure leukaemia?” The Lancet, 1984, vol. 2, No. 8393, pp. 28-30.
Garlie et al. “T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer,” Journal of Immunotherpy, 1999, vol. 22, No. 4, pp. 336-345.
Geppert et al. “Activation of T lymphocytes by immobilized monoclonal antibodies to CD3, regulatory influences of monoclonal antibodies to additional T cell surface determinants.” J. Clin. Invest., 1988, vol. 81, pp. 1497-1505.
Ghosh et al. “Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth.” Journal of the National Cancer Institute, 1995, vol. 87, No. 19, pp. 1478-1483.
Gorelik at al. “Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.” Cancer Immunology Immunotherapy, 1994, vol. 39, No. 2, pp. 117-126.
Grakoui et al. “The immunological synapse: a molecular machine controlling T cell activation.” Science, 1999, vol. 285, No. 5425, pp. 221-227.
Granucci at al. “Transcriptional reprogramming of dendritic cells by differentiation stimuli.” Eur J Immunol, 2001, vol. 31, No. 9, pp. 2539-2546.
Grigg et al. “Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma,” Bone Marrow Transplantion, 1999, vol. 23, No. 2, pp. 107-110.
Grohmann et al. “Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide.” Critical Reviews in Immunology, 1998, vol. 18, Nos. 1-2 pp. 87-98.
Hare et al. “Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2.” Jpn J Cancer Res, 1996, vol. 87, No. 7, pp. 724-729.
Heine et al “A shift in the Th(1)/Th(2) ratio accompanies the clinical remission of systemic lupus erythematosus in patients with end-stage renal disease.” Nephrol Dial Transplant, 2002, vol. 17, No. 10, pp. 1790-1794.
Heniford et al. “Interleukin-8 suppresses the toxicity and antitumor effect of interleukin-2.” Journal of Surgical Research, vol. 56, No. 1, pp. 82-88.
Herlyn et al. “Advances in cancer vaccine development.” Ann Med, 1999, vol. 31, No. 1, pp. 66-78.
Horiguchi et al. “Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells.” Cancer Research, 1999, vol. 59, No. 12, pp. 2950-2956.
Inagawa et al. “Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions.” Anticancer Research, 1998, vol. 18, No. 5D, pp. 3957-3964.
Ito et al. “Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry,” Cancer, 1999, vol. 85, No. 11, pp. 2359-2367.
Janes et al. “Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor.” The Journal of Cell Biology, 1999, vol. 147, No. 2, pp. 447-461.
Jung et al. “CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects.” Blood, 2003, vol. 102, No. 9, pp. 3439-3446.
Kadowaki et at. “Natural type I interferon-producing cells as a link between innate and adaptive immunity.” Human Immunology, 2002, vol. 63, No. 12, pp. 1126-1132.
Kai et al. “Allogeneic hematopoietic stem cell transplantation.” Therap Apher Dial, 2003, vol. 7, No. 3, pp. 285-291.
Kasakura “A role for T-helper type 1 and type 2 cytokines in the pathogenesis of various human diseases.” Rinsho Byori, 1998, vol. 46, No. 9, pp. 915-921.
Kitahara et al. “Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432.” The Journal Laryngology and Otology, 1996, vol. 110, No. 5, pp. 449-453.
Knoefel et al. “Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation.” Journal of Interferon and Cytokine Research, 1997, vol. 17, No. 2, pp. 95-102.
Kobayashi et al. “A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma.” The Journal Immunology, 1998, vol. 160, No. 12, pp. 5869-5873.
Kobayaski et al. “Inhibition of pulmonary metastasis by Z-100, an immunomodulatory lipid-arabinomannan extracted from Mycobacterium tuberculosis, in mice inoculated with B16 melanoma.” Anticancer Drugs, 1997, vol. 8, No. 2, pp. 156-163.
Lahn et al. “Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma.” European Urology, 1999, vol. 35, No. 1, pp. 70-80.
Langenkamp at al. “Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells.” Nature Immunology, 2000, vol. 1, No. 4, pp. 311-316.
Laux et al. “Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and stud

Affiliated with

Also associated with

Rating

Methods for preparing T-cells for cell therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for preparing T-cells for cell therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for preparing T-cells for cell therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4298583